ALEMBIC PHARMA | FDC | ALEMBIC PHARMA/ FDC |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 16.4 | 21.3 | 76.9% | View Chart |
P/BV | x | 6.5 | 4.1 | 158.1% | View Chart |
Dividend Yield | % | 0.6 | 0.0 | - |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ALEMBIC PHARMA Mar-19 |
FDC Mar-18 |
ALEMBIC PHARMA/ FDC |
5-Yr Chart Click to enlarge
|
||
High | Rs | 664 | 319 | 208.2% | |
Low | Rs | 412 | 164 | 251.5% | |
Sales per share (Unadj.) | Rs | 208.7 | 61.6 | 338.6% | |
Earnings per share (Unadj.) | Rs | 31.0 | 9.9 | 311.6% | |
Cash flow per share (Unadj.) | Rs | 37.1 | 12.0 | 310.2% | |
Dividends per share (Unadj.) | Rs | 5.50 | 0 | - | |
Dividend yield (eoy) | % | 1.0 | 0 | - | |
Book value per share (Unadj.) | Rs | 144.2 | 73.2 | 197.1% | |
Shares outstanding (eoy) | m | 188.52 | 174.40 | 108.1% | |
Bonus/Rights/Conversions | - | BB | - | ||
Price / Sales ratio | x | 2.6 | 3.9 | 65.8% | |
Avg P/E ratio | x | 17.4 | 24.3 | 71.5% | |
P/CF ratio (eoy) | x | 14.5 | 20.2 | 71.8% | |
Price / Book Value ratio | x | 3.7 | 3.3 | 113.1% | |
Dividend payout | % | 17.7 | 0 | - | |
Avg Mkt Cap | Rs m | 101,461 | 42,118 | 240.9% | |
No. of employees | `000 | NA | 5.5 | 0.0% | |
Total wages/salary | Rs m | 7,467 | 2,167 | 344.6% | |
Avg. sales/employee | Rs Th | NM | 1,943.7 | - | |
Avg. wages/employee | Rs Th | NM | 391.7 | - | |
Avg. net profit/employee | Rs Th | NM | 313.7 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 39,347 | 10,751 | 366.0% | |
Other income | Rs m | 94 | 510 | 18.4% | |
Total revenues | Rs m | 39,441 | 11,260 | 350.3% | |
Gross profit | Rs m | 8,736 | 2,267 | 385.4% | |
Depreciation | Rs m | 1,152 | 351 | 327.9% | |
Interest | Rs m | 184 | 14 | 1,315.0% | |
Profit before tax | Rs m | 7,493 | 2,411 | 310.8% | |
Minority Interest | Rs m | 11 | -5 | -225.0% | |
Prior Period Items | Rs m | -93 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 1,568 | 671 | 233.5% | |
Profit after tax | Rs m | 5,844 | 1,735 | 336.8% | |
Gross profit margin | % | 22.2 | 21.1 | 105.3% | |
Effective tax rate | % | 20.9 | 27.8 | 75.1% | |
Net profit margin | % | 14.9 | 16.1 | 92.0% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 19,577 | 7,213 | 271.4% | |
Current liabilities | Rs m | 14,896 | 2,104 | 708.1% | |
Net working cap to sales | % | 11.9 | 47.5 | 25.0% | |
Current ratio | x | 1.3 | 3.4 | 38.3% | |
Inventory Days | Days | 90 | 54 | 164.7% | |
Debtors Days | Days | 45 | 28 | 163.6% | |
Net fixed assets | Rs m | 27,097 | 6,865 | 394.7% | |
Share capital | Rs m | 377 | 175 | 215.2% | |
"Free" reserves | Rs m | 26,811 | 12,586 | 213.0% | |
Net worth | Rs m | 27,188 | 12,761 | 213.1% | |
Long term debt | Rs m | 4,993 | 6 | 83,216.7% | |
Total assets | Rs m | 47,778 | 15,041 | 317.6% | |
Interest coverage | x | 41.7 | 173.2 | 24.1% | |
Debt to equity ratio | x | 0.2 | 0 | 39,058.7% | |
Sales to assets ratio | x | 0.8 | 0.7 | 115.2% | |
Return on assets | % | 12.6 | 11.6 | 108.5% | |
Return on equity | % | 21.5 | 13.6 | 158.1% | |
Return on capital | % | 23.6 | 19.0 | 124.5% | |
Exports to sales | % | 0 | 12.3 | 0.0% | |
Imports to sales | % | 0 | 0 | - | |
Exports (fob) | Rs m | NA | 1,327 | 0.0% | |
Imports (cif) | Rs m | NA | NA | - | |
Fx inflow | Rs m | 19,453 | 1,889 | 1,029.9% | |
Fx outflow | Rs m | 6,065 | 0 | - | |
Net fx | Rs m | 13,388 | 1,889 | 708.8% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 8,120 | 1,498 | 541.9% | |
From Investments | Rs m | -7,556 | 201 | -3,757.3% | |
From Financial Activity | Rs m | 590 | -1,694 | -34.8% | |
Net Cashflow | Rs m | 1,153 | 10 | 11,197.1% |
Indian Promoters | % | 74.1 | 68.9 | 107.5% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 2.9 | 4.7 | 61.7% | |
FIIs | % | 9.1 | 7.5 | 121.3% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 13.9 | 19.0 | 73.2% | |
Shareholders | 49,328 | 23,730 | 207.9% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare ALEMBIC PHARMA With: SUN PHARMA PROCTER & GAMBLE HEALTH NOVARTIS UNICHEM LAB ORCHID PHARMA
Compare ALEMBIC PHARMA With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
On Friday, Indian share markets witnessed huge selling pressure and ended deep in the red, amid a global selloff.
For the quarter ended December 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 13.8% YoY). Sales on the other hand came in at Rs 13 bn (up 8.7% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.
For the quarter ended September 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 30.0% YoY). Sales on the other hand came in at Rs 15 bn (up 17.4% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.
For the quarter ended December 2019, FDC LTD. has posted a net profit of Rs 733 m (up 67.7% YoY). Sales on the other hand came in at Rs 3 bn (up 26.0% YoY). Read on for a complete analysis of FDC LTD.'s quarterly results.
For the quarter ended December 2019, ALEMBIC PHARMA has posted a net profit of Rs 2 bn (up 33.3% YoY). Sales on the other hand came in at Rs 12 bn (up 18.8% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.
For the quarter ended September 2019, FDC LTD. has posted a net profit of Rs 627 m (up 45.4% YoY). Sales on the other hand came in at Rs 3 bn (up 28.8% YoY). Read on for a complete analysis of FDC LTD.'s quarterly results.
More Views on NewsIn this video, I'll show you why it might be the right time to take money of the table in pharma stocks.
The pandemic failed to thwart Richa's investing success formula for 2020.
The budget is just a few weeks away. Which stocks can you expect to move? Find out in this video.
Select smallcaps hold a great potential to become the multibaggers of tomorrow. Here's how you could get in early into these stocks.
More